Elicio Therapeutics, Inc. · NASDAQ:ELTX
Elicio Therapeutics — Investor Presentation (September 2026)
31 slides from Elicio Therapeutics's investor presentation, September 2026
Slide 1: Defining the Path Forward for ELI-002 7P in Metastatic and Adjuvant mKRAS PDAC
AMPLIFY-7P Defining the Path Forward for ELI-002 7P in Metastatic and Adjuvant mKRAS PDAC SEPTEMBER 2026 Nasdaq: ELTX
Slide 2: Disclaimers
Disclaimers No Representation or Warranty We do not make and hereby expressly disclaim any representation or warranty, express or implied, as to the reasonableness of the assumptions made in the Presentation or the accuracy or completeness or the information contained in or incorporated by reference
Slide 3: Investment Highlights
Investment Highlights Clinical-stage Biotech Developing Novel Lymph Node-targeted “off the shelf” Cancer Immunotherapies • Designed to generate robust immune responses by targeting lymph nodes- the “brain center” of the immune “AMP” Platform for response Lymph Node Targeting • Proof-of-concept has b
Slide 4: Seasoned Management Team
Seasoned Management Team Robert Connelly Peter DeMuth, PhD Christopher Haqq, MD, PhD Preetam Shah, MBA, PhD Megan Filoon, JD Marc Wolfgang, MS Chief Executive Officer Chief Scientific Officer Executive Vice President, Chief Strategy and General Counsel, Chief Technology Officer Head of Research and
Slide 5: Targeting the Lymph Nodes with AMP to Orchestrate Immunity
Targeting the Lymph Nodes with AMP to Orchestrate Immunity Tissue Injection Site Lymph Node AMP Endogenous Albumin Albumin-bound AMP ➢ APC Activation ➢ T / B Cell Response • Expansion • Persistence • Effector function • Phenotype Albumin-bound AMP Antigen Presenting Cell T Cell B Cell Subcutaneous A
Slide 6: Company Pipeline
Company Pipeline Innovative Pipeline of Cancer Immunotherapies Addressing Critical Unmet Needs Candidate Target Indication Setting Preclinical IND Ready Phase 1 Phase 2 Phase 3 ELI-002 7P mKRAS PDAC Adjuvant Next Step: EOP2 meeting; Selection of Phase 3 regimen to be informed by Phase 1 ELI-002 7P m
Slide 7: ELI-002 7P's Differentiated Approach to mKRAS Therapy
ELI-002 7P’s Differentiated Approach to mKRAS Therapy Validated mKRAS Target | Differentiated Immunotherapy Approach | Clinical Stage Small Molecules Personalized Cancer Vaccines Targeting Lymph Node Targeted Immunotherapy Inhibiting Mutant KRAS Private Tumor Neoantigens Targeting Mutant KRAS FDA ap
Slide 8: Annual U.S. PDAC Addressable Market
Annual U.S. PDAC Addressable Market Significant Addressable Market in Metastatic and Neo/Adjuvant PDAC Annual Incident ELI-002 7P Annual Incident ELI-002 7P Treatment Setting Treatment Setting addressable U.S. Patients (2025) addressable U.S. Patients (2025) Neo/Adjuvant PDAC Metastatic PDAC ~40-50
Slide 9: Metastatic PDAC: Complete Response Observations
ELI-002 7P: Boosting Anti-tumor Immunity Targeting mKRAS Metastatic PDAC: Complete Response Observations
Slide 10: Multiple Confirmed Complete Responses Observed Following ELI-002 7P Treatment, Subsequent Therapy in metastatic PDAC
Multiple Confirmed Complete Responses Observed Following ELI-002 7P Treatment, Subsequent Therapy in metastatic PDAC Hypothesis: ELI-002 7P primes mKRAS-specific immunity to enhance responsiveness to subsequent treatment • 100% confirmed complete radiographic and metabolic responses in three patient
Slide 11: Complete Responses Remain Rare in Metastatic Pancreatic Cancer Across Therapeutic Modalities
Complete Responses Remain Rare in Metastatic Pancreatic Cancer Across Therapeutic Modalities Published studies evaluating chemotherapy, checkpoint inhibitors, and targeted therapies generally report complete response rates ranging from 0–8% Regimen / Study Population CR Signal FOLFIRINOX First Line
Slide 12: Immunotherapy with Chemotherapy or Radiation Has Not Been Effective
Immunotherapy with Chemotherapy or Radiation Has Not Been Effective Historical rates of complete response: 2-6% for Nivo + GnP, 0% for Nivo + SBRT Regimen / Study Population CR Signal Nivo + GnP (PRINCE) First Line (1L) mPDAC 2% (1 / 50) 1 Nivo + GnP First Line (1L) mPDAC 3% (1 / 34) 2 Nivo + SBRT S
Slide 13: Complete Responses Observed Following ELI-002 7P and Subsequent Checkpoint Inhibition
Complete Responses Observed Following ELI-002 7P and Subsequent Checkpoint Inhibition Three patients who recurred following ELI-002 7P treatment subsequently achieved complete radiographic response, complete metabolic response, and biomarker normalization after nivolumab-based therapy 3 / 3 Patients
Slide 14: Complete Responses Were Confirmed and Durable
Complete Responses Were Confirmed and Durable 1 Durable complete responses observed following subsequent nivolumab-based therapy in three patients previously treated with ELI-002 7P Patient Tumor mKRAS Nivo start → PR / CR DOR 1 Current Status 2.2 mo PD, SBRT, FOLFOX-Nivo, Ipi/Nivo, Patient 1 G12D 6
Slide 15: Patient 1: Complete Response Following ELI-002 7P and Subsequent Nivolumab
Patient 1: Complete Response Following ELI-002 7P and Subsequent Nivolumab Complete Radiographic, Metabolic, and Biomarker Resolution of Multifocal Para-esophageal and Mesenteric Nodes Patient 1: CA19-9 Tumor Biomarker Values, Treatment Timeline Patient 1: PET / CT Week 18 Week 45 Week 18: Week 45:
Slide 16: Patient 2: Complete Response Following ELI-002 7P and Subsequent Nivolumab
Patient 2: Complete Response Following ELI-002 7P and Subsequent Nivolumab Complete Radiographic, Metabolic, and Biomarker Resolution of Gastro-hepatic Ligament Nodes Patient 2: CA19-9 Tumor Biomarker Values, Treatment Timeline Patient 2: PET / CT Week 28 Week 69 Week 28: Week 69: PET / CT PET / CT
Slide 17: Patient 3: Complete Response Following ELI-002 7P and Subsequent Nivolumab
Patient 3: Complete Response Following ELI-002 7P and Subsequent Nivolumab Complete Metabolic, and Biomarker Resolution of Mesenteric Local Recurrence Patient 3: CA19-9 Tumor Biomarker Values, Treatment Timeline Patient 3: PET / CT Week 35 Week 48 Week 35: Week 48: PET / CT PET / CT SUVmax 8.6 SUVma
Slide 18: Hypothesized Mechanism for Complete Responses Following ELI-002 7P and Subsequent Therapy
Hypothesized Mechanism for Complete Responses Following ELI-002 7P and Subsequent Therapy ELI-002 7P may prime durable mKRAS-specific immunity important for responses to subsequent therapy Historical Observations: Subsequent Therapy Modulation of Tumor Deep Tumor Responses (Chemo, PD-1 Inhibition →
Slide 19: T cell Infiltration after ELI-002 7P Preceded Complete Responses
T cell Infiltration after ELI-002 7P Preceded Complete Responses Observations of increased T cell tumor infiltration, and modulation of tumor PD-L1 following recurrence after ELI-002 7P Patient 1 Primary Tumor Metastatic Relapse Patient 2 Primary Tumor Metastatic Relapse Post-ELI-002 7P, prior to Po
Slide 20: mKRAS-specific T cell responses persisted through subsequent chemotherapy and nivolumab treatment
mKRAS-specific T cell responses1 persisted through subsequent chemotherapy and nivolumab treatment Patient 1 Patient 2 Patient 3 % IL2+ IFNγ+ and/or TNFα+ among CD8+ T cells 800 0.8 800 IFN and/or GrB SFC / 1x106 PBMC IFN and/or GrB SFC / 1x106 PBMC 600 0.6 600 400 0.4 400 200 0.2 200 0 0.0 0 ELI-
Slide 21: Complete Responses Associated with Personalized T Cell Responses
Complete Responses Associated with Personalized T Cell Responses 3 / 3 complete responses were associated with modulation of antigen spreading T cell responses Patient 1 Patient 2 Patient 3 % of Assayed Personalized 10 10 10 Tumor Antigens Tumor Antigens Assayed Tumor Antigens Assayed Tumor Antigens
Slide 22: Metastatic PDAC Phase 1 Development Strategy
Metastatic PDAC Phase 1 Development Strategy Plans for a staged development pathway designed to evaluate ELI-002 7P + RASi +/- CPI across metastatic PDAC settings metastatic PDAC: ELI-002 + RASi combination Inform Future metastatic & → Adjuvant Phase 3 Development metastatic PDAC: ELI-002 + RASi + C
Slide 23: Adjuvant PDAC: AMPLIFY Phase 2 Analysis
ELI-002 7P: Boosting Anti-tumor Immunity Targeting mKRAS Adjuvant PDAC: AMPLIFY Phase 2 Analysis
Slide 24: AMPLIFY-7P: Randomized Phase 2 Trial in Adjuvant mKRAS+ PDAC
AMPLIFY-7P: Randomized Phase 2 Trial in Adjuvant mKRAS+ PDAC CLINICAL STUDY OVERVIEW: NCT05726864 (2:1 Randomized) Designed to evaluate whether ELI-002 7P could improve disease-free survival following standard locoregional therapy ELI-002 7P Monotherapy Endpoints • 7 mKRAS peptide antigens ELI-002 7
Slide 25: Early DFS Separation Observed Through Months
Early DFS Separation Observed Through 9 Months 1 DFS analysis at 3- and 6-months indicate early clinical activity, with treatment-arm separation persisting through 9 months ELI-002 7P DFS: ITT Stratified ELI-002 7P DCO 20-APR-2026 Dosing Period ELI-002 7P 23.8 (9.8, NE) 1.0 Median DFS p-Value = 0.53
Slide 26: mKRAS-Specific T Cell Responses Were Strongly Associated with Improved DFS
mKRAS-Specific T Cell Responses Were Strongly Associated with Improved DFS Greater mKRAS-specific T cell responses were associated with longer DFS following ELI-002 7P treatment mKRAS T cell fold- Ph1-defined 9.17x Threshold 1 100 change from baseline: ELI-002 7P DFS: ITT Supervised by mKRAS- >9.17x
Slide 27: ELI-002 7P Demonstrated a Favorable Safety and Tolerability Profile
ELI-002 7P Demonstrated a Favorable Safety and Tolerability Profile Safety profile supports extended treatment and combination strategies ELI-002 7P SOC Proportionally Fewer Adverse Events Observed vs. SOC Category n (%) n (%) • Proportionally fewer ELI-002 7P patients had adverse events Any TEAE 70
Slide 28: A Precision Medicine Roadmap to Adjuvant PDAC Pivotal Phase 3
A Precision Medicine Roadmap to Adjuvant PDAC Pivotal Phase 3 Key Phase 2 findings inform the Phase 3 development strategy Focus on patients with the greatest potential to benefit from treatment based on subgroup Refine Patient Eligibility analyses Robust early efficacy during the dosing period with
Slide 29: A Substantial Post-Surgical Treatment Gap Remains in Adjuvant PDAC
A Substantial Post-Surgical Treatment Gap Remains in Adjuvant PDAC Observation remains standard of care despite substantial recurrence risk after surgery and chemotherapy >50% Current treatment course leaves a major post-surgical recurrence gap Recurrence within 12-months 1 Surgery Peri-operative /
Slide 30: Next Steps: Advancing Clinical Development of ELI-002 7P in Metastatic PDAC
Next Steps: Advancing Clinical Development of ELI-002 7P in Metastatic PDAC in Combination with Checkpoint Inhibition and Other Therapies 01 Finalize Study Design Initiate Phase 1 Study in mPDAC, anticipated Q4 2026 with readouts 02 anticipated 3-6 months after study start Inform future development
Slide 31: 31
31
Elicio Therapeutics — Investor Presentation (September 2026) on 6ix